Research protocol for the validation of a new portable technology for real-time continuous monitoring of Early Warning Score (EWS) in hospital practice and for an early-stage multistakeholder assessment

Abstract

IntroductionThe real-time continuous monitoring of vital parameters in patients affected by multiple chronic conditions and/or COVID-19 can lead to several benefits to the Italian National Healthcare System (IT-NHS). The UBiquitous Integrated CARE (UBICARE) technology is a novel health digital platform at the validation stage in hospital setting. UBICARE might support the urgent need for digitalisation and early intervention, as well as minimise the face-to-face delivery of care in both hospital and community-based care settings. This research protocol aims to design an early-stage assessment of the multidimensional impact induced by UBICARE within the IT-NHS alongside technology validation in a hospital ward.Methods and analysisThe targeted patients will be medium/high-risk hypertensive individuals as an illustrative first example of how UBICARE might bring benefits to susceptible patients. A mixed-method study will be applied to incorporate to the validation study a multistakeholder perspective, including perceived patient experiences and preferences, and facilitate technology adoption. First, semistructured interviews will be undertaken with a variety of stakeholders including clinicians, health managers and policy-makers to capture views on the likely technology utility, economic sustainability, impact of adoption in hospital practice and alternative adoption scenarios. Second, a monocentric, non-randomised and non-comparative clinical study, supplemented by the administration of standardised usability questionnaires to patients and health professionals, will validate the use of UBICARE in hospital practice. Finally, the results of the previous stages will be discussed in a multidisciplinary-facilitated workshop with IT-NHS relevant stakeholders to reconcile stakeholders’ perspectives. Limitations include a non-random recruitment strategy in the clinical study, small sample size of the key stakeholders and potential stakeholder recruitment bias introduced by the research technique.Ethics and disseminationThe Ethics Committee for Clinical Experimentation of Tuscany Region approved the protocol. Participation in this study is voluntary. Study results will be disseminated through peer-reviewed publications and academic conferences.

A systematic literature review of Real-World Evidence (RWE) on post-market assessment of medical devices

“…Even though in recent years there has been an increasing understanding of the need to seek a broader approach by considering additional parameters of bene t to the traditional ones (i.e., clinical and/or economic), only few publications assessed organizational requirements and/or human factors, which were reduced to usability and/or acceptability excluding a considerable contribution to the assessment in terms of human e cacy and effectiveness (19,(147)(148)(149)(150).…”

“…Historically, the object of HTA has been restricted to pharmaceuticals, rather than MDs, and evidence on clinical e cacy/effectiveness (i.e., can it work/does it work) and/or cost-effectiveness (i.e., is it worth it) has formed a key part of the formal assessment, taking over other relevant evidence types (e.g., human factor) when assessing the impact of a healthcare innovation (1,19,20). In terms of evidence generation, HTA has been traditionally based on positive scienti c methods, such as systematic reviews and randomized controlled trials (RCTs), which have been preferred due to their lower risk of bias by design compared to real-world studies (21).…”

Assessing the Social and Environmental Impact of Healthcare Technologies: Towards an Extended Social Return on Investment

“…The final aim of this method is to select the most promising biomedical technologies, which can reach patients and society in a timelier fashion. HTA is the systematic assessment of the costs and multidimensional consequences of a medical technology [ 24 , 25 , 26 , 27 ]. Recently, there has been an increasing attention to achieve a broader view in HTA by enlarging the scope of analysis and including social, ethical, safety-related or environmental parameters of benefit [ 25 , 28 ].…”

Adoption of novel biomarker test parameters with machine learning‐based algorithms for the early detection of sepsis in hospital practice

“…Exploring multifactorial determinants of technology acceptance by nurses and other professionals is strategic for management to support adoption within a health organization through tailored strategies leading to organizational flexibility (Manetti et al, 2017(Manetti et al, , 2020. A qualitative research design was employed to generate rich information allowing for an in-depth understanding of nurses' and other professionals' determinants, motivations, and emotional perceptions concerning technology adoption and organizational change.…”